PRLD.O (PRLD.O) News
Follow PRLD.O (PRLD.O) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 3 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Prelude Therapeutics Participates in Chardan Healthcare Conference
Prelude Therapeutics will participate in the Chardan Healthcare Conference in New York City on October 20, 2026. Chief Scientific Officer Peggy Scherle and Chief Financial Officer Bryant Lim will join a fireside chat at
NEWS | Oct 16, 2026, 08:03 PM UTC
L
BRIEF — Prelude Announces Clinical Trial Collaboration And Supply Agreement With Lilly To Evaluate KAT6A Selective Degrader PRT13722 In Combination With Verzenio® And Inluriyo® In Patients With HR+/HER2 — Breast Cancer
Oct 13 (Reuters) — Prelude Therapeutics Incorporated: Prelude Announces Clinical Trial Collaboration And Supply Agreement With Lilly To Evaluate Kat6a Selective Degrader Prt13722 In Combination With Verzenio® And Inluriy
NEWS | Oct 13, 2026, 12:15 PM UTC
L
Prelude Therapeutics partners with Lilly to test PRT13722 combos with Verzenio, imlunestrant in Phase 1 breast cancer trial
Prelude Therapeutics entered a clinical trial collaboration and supply agreement with Lilly for abemaciclib and imlunestrant. Deal supports a Phase 1 study of PRT13722 combinations with abemaciclib or imlunestrant in HR+
REGULATION | Oct 13, 2026, 11:07 AM UTC